PHARMA MAR, S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.56 EUR | -0.90% |
|
+8.54% | -30.67% |
| Apr. 23 | Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
| Sales 2025 * | 196M 210M | Sales 2026 * | 238M 256M | Capitalization | 508M 545M |
|---|---|---|---|---|---|
| Net income 2025 * | 56M 60.07M | Net income 2026 * | 91M 97.62M | EV / Sales 2025 * | 1.66 x |
| Net cash position 2025 * | 184M 197M | Net cash position 2026 * | 278M 298M | EV / Sales 2026 * | 0.97 x |
| P/E ratio 2025 * |
11.2
x | P/E ratio 2026 * |
5.82
x | Employees | 509 |
| Yield 2025 * |
1.71% | Yield 2026 * |
2.28% | Free-Float | 74.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharma Mar, S.A.
More press releases
More news
| 1 day | +0.94% | ||
| 1 week | +11.05% | ||
| Current month | +1.39% | ||
| 1 month | +3.55% | ||
| 3 months | -28.12% | ||
| 6 months | -2.87% | ||
| Current year | -29.07% |
1 week
26.52
29.50
1 month
26.1629.50
Current year
26.1642.80
1 year
26.1643.92
3 years
26.16101.35
5 years
17.66148.00
10 years
10.45148.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 86-04-29 | |
| Director of Finance/CFO | - | 87-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 86-04-29 | |
| Director/Board Member | - | 86-04-29 | |
| Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.26% | 114 M€ | +8.30% | - | |
| 0.04% | 2 M€ | -.--% | ||
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 28.48 | -1.18% | 15 997 |
| 24-04-25 | 28.82 | +1.41% | 58,934 |
| 24-04-24 | 28.42 | +2.97% | 122,458 |
| 24-04-23 | 27.6 | +4.07% | 36,585 |
| 24-04-22 | 26.52 | +1.07% | 22,672 |
Delayed Quote BME, April 26, 2024 at 03:45 am EDT
More quotes
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
28.82
EUR
Average target price
49.2
EUR
Spread / Average Target
+70.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.07% | 545M | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.51% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.34% | 8.75B |
- Stock Market
- Equities
- PHM Stock
